Robert Jeffrey Kaner, M.D.
Dr. Kaner is Associate Attending Physician at the New York Presbyterian Weill Cornell Center and Assciate Professor ofClinical Medicine and Genetic Medicine at Weill Cornell Medical College. He has expertise in interstitial lung diseases suchas idiopathic pulmonary fibrosis (IPF) and including those due to connective tissue diseases and directs a multidisciplinaryinterstitial lung disease conference. He has clinical expertise in lung complications of conditions such as HIV, cancer andcancer treatment including chemotherapy, radiation and bone marrow transplantation. He is the medical director of the VentilatorManagement Team.
Dr. Kaner is the Principal Investigator of the Weill-Cornell site of the National Instituteof Health (NIH)-sponsored Idiopathic Pulmonary Fibrosis Clinical Research Network, one of 11 in the US and the only centerin the Northeast/Mid-Atlantic region of the country. He is the project leader of an NIH-sponsored study of the molecular basisof accelerated emphysema development in HIV-1 positive smokers, which is part of a Specialized Center of Clinically OrientedResearch for chronic obstructive pulmonary disease (COPD) directed by Dr. R. Crystal. He has served as principal investigatorof NIH-sponsored basic research in mechanisms of vascular permeability in the lung and interactions of human alveolar macrophageswith HIV-1. He has participated in multicenter research studies in severe sepsis and nosocomial pneumonia.
Dr. Kaner is committed to research into the application of cutting edge molecular techniques to advance the understandingof pathophysiology, as well as to further improve the diagnosis and treatment of lung disease. He is board certified in internalmedicine, pulmonary disease and critical care medicine.
Internship: Hospital of the University of Pennsylvania,
Residency: Hospital of the University of Pennsylvania,
Fellowship: Pulmonary and Critical Care Medicine, Hospital of
the University of Pennsylvania, Philadelphia, PA
Fellowship (research): Connective Tissue Research Institute,
University of Pennsylvania, Philadelphia, PA
Director, Ventilator Management Team, New York-Presbyterian
Hospital/Weill Cornell Campus, New York, NY
Outstanding Clinician Award, NY State Thoracic Society, 2010
Stover DE and Kaner RJ. Pulmonary Toxicity in DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th edition. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011
Kaner RJ. Pulmonary Complications of Allogeneic Bone Marrow Transplantation. Pulmonary Up-To-Date Series on CD, 1996-2013.
Kaner RJ.. Pulmonary Complications of Autologous Bone Marrow Transplantation. Pulmonary Up-To-Date Series on CD, 1996-2013.
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, Kaner RJ, Olman MA; The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Am J Respir Crit Care Med. 2012 May 3.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. (Kaner RJ, collaborating investigator) N Engl J Med. 2012 May 24;366(21):1968-77
A Comparison of Seriously Ill Patients with or without AIDS Requiring Prolonged Mechanical Ventilation. J Dermot Frengley, M.D.; Giorgio R Sansone, Ph D; Kiranjit Uppal, M.P.H; John J Vecchione, M.D; Robert J Kaner, M.D J Crit Care. 2012 Dec;27(6):594-601
Mast Cells: A Pivotal Role in Pulmonary Fibrosis. Arul Veerappan, Nathan J. O’Connor, Jacqueline Brazin, Alicia C. Reid, Albert Jung, David McGee, Barbara Summers, Dascher Branch-Elliman, Brendon Stiles, Stefan Worgall, Robert J. Kaner and Randi B. Silver DNA AND CELL BIOLOGY Volume 32, Number 4, 2013 206–218
Effects of smoking on non-AIDS-related morbidity in HIV-infected patients. Shirley DK, Kaner RJ, Glesby MJ. Clin Infect Dis. 2013 Jul;57(2):275-82.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [PPO]
- AETNA [Medicare]
- AETNA [HMO]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
Stover DE and Kaner RJ. Pulmonary Toxicity in DeVita VT, Hellman S and Rosenberg SA eds): Cancer Principles and Practice of Oncology, 7th Edition, J.P. Lippincott. 2535-2545, 2005.
Kaner RJ. Pulmonary Complications of Allogeneic Bone Marrow Transplantation.Pulmonary Up-To-Date Series on CD, 1996-2005..
Kaner RJ, Worgall S, Leoold PL, Stolze E, Milano E, Hidaka C, Ramalingam R, Hackett NR, Singh R, Bergelson J, Finberg R, Falck-Pedersen E, and Crystal RG. Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie /adenovirus receptor. Am J Respir Cell Mol Biol, 1999; Mar 1;20(3):361-370.
Kaner RJ, Ladetto J, Singh R, Fukuda N, Matthay M and Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 22:657-664, 2000.
Kaner RJ and Crystal RG. Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Molecular Medicine, April 2001; 7(4):240-246.
Kaner RJ, Crystal RG. Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak? High Alt Med Biol. 2004;5(4):399-409.
Honors and Awards
Alpha Omega Alpha, University of Pennsylvania School of
Dalsemar Research Scholar Award: American Lung Association
Clinical Investigator Development Award: National Institutes of
Service Excellence Award, New York Presbyterian Hospital
Principal Investigator, Idiopathic Pulmonary Fibrosis Clinical
Research Network: National Institutes of Health (2005)
- Interstitial Pulmonary Fibrosis
- Fibrosis of Lung
- Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Chronic Obstructive Pulmonary Disease (COPD)
- Internal Medicine
- Pulmonary Disease Medicine
- Critical Care Medicine
- M.D., University of Pennsylvania School of Medicine, 1982